InvestorsHub Logo
icon url

rosemountbomber

07/06/20 8:19 AM

#284632 RE: Ray #284631

Could not agree more Ray
icon url

Invest83838

07/06/20 9:56 AM

#284639 RE: Ray #284631

Why Ray?

JT going "all in" on the appeal case

because even if AMRN loses

JT and his management team can continue milking this to at least 2029 and probably beyond

by doing more dilutions and giving themselves more free shares

while they try to expand sales in rest of the world

and probably making some kind of profit

and JT & team will be the good guys

since the bad guy generics and the US court system screwed poor little AMRN
icon url

rafunrafun

07/06/20 4:30 PM

#284701 RE: Ray #284631

I don't see this happening. The way the EPA market will be shaping up by 2029, we'll have Amarin, Hikma, Apotex, Teva & DR.

If Amarin settles with H & R, it will no longer be August 2029, but earlier. Then why wouldn't multiple generics do the same - demand a ransom (earlier market entry and/or cash and/or other countries)? At what point does it stop?